Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
A Phase II Study of Ferumoxytol and Gadolinium Magnetic Resonance Imaging at 3T and 7T in Subjects With Primary or Metastatic Brain Tumors Either Before or After Therapy
Sponsor: National Cancer Institute (NCI)
Terminated
Loss of funding
Other terminated trials from National Cancer Institute (NCI)
Listed as NCT00659126, this PHASE2 trial focuses on Metastatic Malignant Neoplasm in the Brain and Primary Brain Neoplasm and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Oct 2023 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Feb 2021 — Dec 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .